Literature DB >> 12788589

Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries.

Luis Jódar1, F Marc LaForce, Costante Ceccarini, Teresa Aguado, Dan M Granoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12788589     DOI： 10.1016/S0140-6736(03)13494-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  27 in total

Review 1.  Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.

Authors:  Amy C Sherman; David S Stephens
Journal:  Expert Rev Vaccines       Date:  2020-04-29       Impact factor: 5.217

2.  A study of physico-chemical interactions between Haemophilus influenzae type b and meningococcus group C conjugate vaccines.

Authors:  Robert B D Otto; Dennis T Crane; Barbara Bolgiano
Journal:  Afr Health Sci       Date:  2007-12       Impact factor: 0.927

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVacR).

Authors:  Prasad S Kulkarni; Suresh S Jadhav; F Marc LaForce
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

5.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

6.  Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989.

Authors:  Gunnstein Norheim; Einar Rosenqvist; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; E Arne Høiby; Tsegaye Alebel; Degu Berhanu; Yarid Merid; Morten Harboe; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

7.  Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.

Authors:  H Findlow; B D Plikaytis; A Aase; M C Bash; H Chadha; C Elie; G Laher; J Martinez; T Herstad; E Newton; S Viviani; C Papaspyridis; P Kulkarni; M Wilding; M P Preziosi; E Marchetti; M Hassan-King; F M La Force; G Carlone; R Borrow
Journal:  Clin Vaccine Immunol       Date:  2009-05-27

Review 8.  Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".

Authors:  Lee M Wetzler; Ian M Feavers; Scott D Gray-Owen; Ann E Jerse; Peter A Rice; Carolyn D Deal
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

9.  Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Authors:  P T Beernink; D A Caugant; J A Welsch; O Koeberling; D M Granoff
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

10.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.